William Osler Health System

Brampton, Ontario L6R3J7

2 studies enrolling now · 16 studies all time

What they study most

ARDS, Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC), Antimicrobial, Bacteremia, Bile Duct Cancer, Bladder Cancer, Breast Cancer, COVID-19, Carcinoma, Non-Small-Cell Lung, Cholangiocarcinoma, Colorectal Cancer, Community-acquired Pneumonia, Influenza, COVID-19

Studies at this site

• Platform of Randomized Adaptive Clinical Trials in Critical Illness — Recruiting now
• Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia — Recruiting now
• A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy — Running, not enrolling
• A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer — Running, not enrolling
• A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis — Running, not enrolling
• TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations — Running, not enrolling
• Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05) — Completed
• Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer — Running, not enrolling
• Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors — Stopped early
• A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of EB05 + SOC Vs. Placebo + SOC in Adult Hospitalized Patients with COVID-19 — Paused
• A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100) — Completed
• Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness — Completed
• Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors — Running, not enrolling
• Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) — APPROVED_FOR_MARKETING
• Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir/Pibrentasvir in Chronic Hepatitis C Patients — Completed
• Remote Ischemic Conditioning Using the autoRIC — Status unconfirmed